Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · May 18, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new type of radiation treatment for men with intermediate or high-risk prostate cancer. The researchers want to see if a targeted approach, which focuses on the tumor itself, is better than the standard treatment that targets the entire prostate. They believe that by focusing the radiation only on the tumor, they can reduce side effects on nearby organs, such as the bladder and intestines. Throughout the study, they will track any side effects, how well the treatment works, and how it affects patients' quality of life.

To participate in this trial, men must be at least 18 years old and have a confirmed diagnosis of prostate cancer that needs treatment. They should also have a visible tumor seen on imaging tests. Participants will need to agree to follow all study procedures and use effective contraception during the treatment period if applicable. It's important to note that this trial is not yet recruiting participants, so it will start in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Provision of signed and dated informed consent form
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• • At least 18 years old
• • Histologic confirmation of prostate adenocarcinoma with plan for curative-intent radiation therapy
• • Lesion visible on prostate Magnetic Resonance Imaging and/or Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography (according to the treating physician) with concordant pathology from biopsy needle locations.
• • For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner during the radiation therapy treatment and for at least 6 months afterward.
• Exclusion Criteria:
• • Bilateral hip implants
• • Prior prostatectomy
• • Prior prostate cancer treatment (for example, focal therapy). Note that participants who started hormone therapy within the 90 days prior to randomization are eligible, as long as study-compatible imaging was performed within the 4 months prior to starting the hormone therapy.
• • Prior radiation therapy to an area requiring treatment in the present study